Company News

For anyone pioneering a new technology in regenerative medicine, it’s not long before you are asked what it is that sets your tech apart from the rapidly growing number of other competing [...]

What role could clay play in the biomedical field and why is Renovos Biologics focussing on this industrial-type material for cutting edge regenerative medicine technologies? It is an interesting [...]

I’m a chemist working on clay for a biologics company. That may well sound like a juxtaposition. Add to that the fact that the biological application isn’t to do with creatures in the [...]

Key read for nanoclays in drug delivery – group’s new publication on nanoclay in Nature Communications! The paper, which can be found here, reports on the use of bisphosphonate [...]

Renovos and our advanced nanoclay biomaterial, Renovite®, has been featured in Orthoworld. The article, “Renovos to Develop Next-Gen Technology to “Tame” BMP-2 Diffusion”, outlines key issues [...]

Renovos has recently been awarded one of the very first charity investments in the UK. In a progressive move to find new ways to support people living with painful and debilitating bone and joint [...]

The synthetic nanoclay gel scaffold effectively localises new bone formation (in red). It offers injectable delivery and retention of biologics, released only to in-growing cells for efficacy at [...]

  The Redefining Early Stage Investments (RESI) Conference took place on Wednesday 11th September 2019 in Boston. The organisers at Life Science Nation (LSN) invite all global early-stage [...]

Working with Caltag Medsystems at BRS/BORS 2019 to spead the word about Renovos and our mesenchymal stem cell products. Together with Hannah from Caltag Medsystems, Renovos participated in Bone [...]

Simon Sinclair Previously in clinical trials at Merck & Co. Inc. and in medical affairs at DePuy Synthes and Johnson & Johnson, Simon is now working in safety and vigilance at RB. This [...]